Veracyte (VCYT) late Tuesday said new data from a clinical trial showed its whole-genome sequencing-based platform detected cancer recurrence in patients treated for muscle-invasive bladder cancer with greater accuracy than droplet digital PCR-based blood testing and earlier than standard imaging.
The company presented the findings at the annual European Association of Urology Congress in Madrid, Spain.
The study enrolled 100 patients undergoing neoadjuvant chemotherapy and radical cystectomy. According to the company, the whole-genome sequencing platform had a negative predictive value of 95.9% compared to 96.2% for blood testing after six months, while demonstrating an 88% specificity rate compared to 62% for patients tested with the blood-based method.
The platform also detected cancer recurrence a median of 93 days earlier than imaging, the company added.
Veracyte plans to launch its first minimal residual disease test for muscle-invasive bladder cancer in the first half of 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。